Clinical Trial Update: Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating anlotinib combined with penpulimab as first-line therapy for advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Penpulimab

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN